drugset
drugset / Trial / NCT04518137

A Study of Evaluating the Safety and Efficacy of ATG-008 for Advanced Solid Tumors (BUNCH)

NCT04518137 ↗

Phase 2 Terminated 5 enrolled Antengene Corporation
NaSingle-groupOpen-labelTreatment

Summary

This is a single-arm and open-label study of ATG-008 for the Treatment of Patients With advanced Solid Tumors harboring NFE 2L2, STK11, RICTOR or other specific genetic alterationts

Timeline

Start
2021-04-09
Primary completion
2022-05-30
Completion
2022-05-30

Drugs

EvaluationDrugModalityDoseRoute
Subject ONATASERTIB Small molecule 30 mg Oral

Indications

cancer